REVELATION BIOSCIENCES, INC. Deferred Tax Assets, Operating Loss Carryforwards
REVELATION BIOSCIENCES, INC. (REVB) had Deferred Tax Assets, Operating Loss Carryforwards of $14.38 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $14.38M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $10.95M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $7.28M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $5.51M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $14.38M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $10.95M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $7.28M 10-K · filed 2025-03-06 | |
| 2022-12-31 | $5.51M 10-K/A · filed 2024-09-23 | |
| 2021-12-31 | $3.52M 10-K · filed 2023-03-30 | $3.28M 10-K · filed 2022-04-15 |
| 2020-12-31 | $35.00K 10-K/A · filed 2021-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |